Deal Snapshot
FTC CLEARS US GENERIC DRUG SPECIALISTS AMNEAL AND IMPAK TO CLOSE MERGER
Monday 30 April 2018

The US Federal Trade Commission has cleared US-based drugmakers Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) to close their planned business combination in an all-stock transaction, the companies said.
The parties have now obtained all regulatory approvals required to close the transaction. Accordingly, the parties expect to consummate the business combination following the close of trading on 4 May 2018.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 30/04/2018
Target: Impax Laboratories
Country: USA
Deal Size: 6bn (USD)
Sector: Pharmaceuticals
Type: Merger
Financing: Stock
Status: Agreed
Vendor:
Buyer: Amneal Pharmaceuticals
Buyer Advisor: J.P. Morgan Securities , Latham and Watkins
Comment:


Options